Year Later, Indian Import Duties Still In Place On Cancer Drugs
This article was originally published in PharmAsia News
Import duties still in place in India on the most promising cancer drugs are keeping the price to Indians at about 35 percent more than prices charged elsewhere in the world. The import duties were to have been lifted early last year on certain life-saving drugs, but red tape apparently has delayed the exemptions. A Finance Ministry official said the agency still had not received a recommendation from the Health Ministry for drugs to be placed on a list of exempted drugs. The government had listed 14 cancer drugs that were supposed to be exempt from countervailing duties and have import duties reduced to 5 percent. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.